Endra Life Sciences (NDRA): CEO received 75K shares

75K

Shares

Traded

Jan 21, 2026

Filed

Jan 24, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 28, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 28, 2025, ENDRA Life Sciences Inc. (the “Company”) entered into a Consulting Agreement with Michael Thornton (the “Consulting Agreement”), in connection with which Mr. Thornton resigned as the Company’s Chief Technology Officer effective on such date.”
2. Dec 9, 2025Company filing · Form 8-K · Executive change, Bylaws or charterChanged a top executive or board member, and changed its bylaws, charter or fiscal year (and 1 more item)“On December 9, 2025, the stockholders of ENDRA Life Sciences Inc. (the “Company”) approved the Second Amendment to the Company’s 2016 Omnibus Incentive Plan (the “Omnibus Plan Amendment”) at the 2025 Annual Meeting of the Company’s Stockholders (the “Annual Meeting”).”

What came next

1. Mar 19, 2026Company filing · Form 8-K · Restructuring, Reg FDAnnounced job cuts, closures or a restructuring, and shared information with investors“On March 25, 2026, ENDRA Life Sciences Inc. (the “Company”) announced that it has initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value.”
2. Mar 31, 2026Company filing · Form 8-K · ResultsReported its results
3. Apr 20, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“As previously reported, on May 27, 2025, the Company received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Staff (the “Staff”) notifying the Company that its stockholders’ equity had fallen below the $2,500,000 required minimum for continued listing set forth in Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Requirement”).”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Endra Life Sciences

For Endra Life Sciences, OQRO holds 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its NDRA page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Endra Life Sciences

• SEC Schedule 13GNov 10, 2026
• SEC Schedule 13DOct 8, 2026

Everything OQRO holds on this company is on its NDRA page.